Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

On Friday, the FDA approved CRISPR's Casgevy gene-editing treatment for sickle cell anemia. Analysts are mixed in their opinions on how big a deal this is for CRISPR.

Why CRISPR Stock Keeps Falling

CRISPR (CRSP) and Vertex announce the FDA approval of the first-ever CRISPR-based gene-editing therapy, Casgevy, for the treatment of sickle cell disease.

CRISPR (CRSP), Vertex Fall Despite FDA Nod to SCD Drug Casgevy

After reaching an important support level, CRISPR Therapeutics AG (CRSP) could be a good stock pick from a technical perspective. CRSP recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

After Golden Cross, CRISPR Therapeutics AG (CRSP)'s Technical Outlook is Bright

CRISPR Therapeutics ( CRSP ) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old defense mechanism bacteria use to battle viruses. CRISPR -- which stands for clustered regularly interspaced short palindromic repeats -- was discovered and described as a potential gene modifying treatment in a paper published in 2012 by biochemist Jennifer Doudna and microbiologist Emmanuelle Charpentier.

Bull of the Day: CRISPR Therapeutics (CRSP)

CRISPR Therapeutics received marketing approval from the U.S. Food and Drug Administration for its first drug, called Casgevy, on Dec. 8. Shares of CRISPR Therapeutics fell sharply in response to what seemed like great news.

Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?

Vertex Pharmaceuticals

The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.

The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person

The FDA has granted approval to a CRISPR-based gene editing therapy for the first time in history, validating the approach. The therapy, called Casgevy, is approved to treat Sickle Cell Disease after showing positive results in clinical trials, functionally curing patients. Despite the approval, the stock prices of CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated did not surge today, possibly due to concerns about market potential and competition from another approved therapy.

Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed

Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced Friday that the Food and Drug Administration (FDA) gave them approval for use of the first-ever gene-editing therapy using CRISPR technology in the U.S.

Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US

Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.

Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). This approval means that for the first time, approximately 16,000 patients.

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Crispr Therapeutics AG CRSP, -5.37% and Vertex Pharmaceuticals Inc. VRTX, -1.25% on Friday got U.S. regulatory approval for a treatment for sickle-cell disease based on the transformative gene-editing technology Crispr.

Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment

The Crispr Therapeutics (NASDAQ: CRSP) stock price moved sideways after the Food and Drug Administration (FDA) approved Casgevy. The shares were trading at $70.30 on Friday, where they have been in the past few days.

CRISPR, VRTX stock prices waver as US FDA approves Casgevy

bluebird bio

The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.

US approves two gene therapies for sickle cell disease

Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.

U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease

Crispr stock rose early Friday ahead of the FDA's expected approval of a groundbreaking gene-editing treatment.

Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment

CRISPR Therapeutics could commercialize its first medicine in the U.S. very soon. Yet, it laid off a significant portion of its workforce in advance of that possibility.

CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?

The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.

U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients

American Tower

Amazon

CrowdStrike

Alphabet

Lovesac Company

Okta

PayPal

Western Digital

There has been no shortage of next-big-thing trends for investors to latch onto over the past three decades. Some of this year's hottest trends, including artificial intelligence (AI) and electric vehicles (EVs), could falter in 2024.

5 Unstoppable Trends to Invest $1,000 in for 2024

Caribou Biosciences

Gilead Sciences

Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

CRISPR Therapeutics is cutting two of its more advanced candidates in favor of two next-generation ones. The company is also awaiting a key regulatory decision on Friday.

Is This News a Setback or a Step Forward for CRISPR Therapeutics?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?

The consensus price target hints at a 27.2% upside potential for CRISPR Therapeutics AG (CRSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 27.15%: Read This Before Placing a Bet

Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

Invitae

CRISPR Therapeutics may soon generate its first product revenue. Invitae, making progress in its recovery plan, could climb if it meets its goals.

Better Growth Stock: CRISPR Therapeutics vs. Invitae

-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70-

News for CRISPR Therapeutics Stock (CRSP)